JPH02286172A - Leucocyte separating filter in platelet preparation - Google Patents
Leucocyte separating filter in platelet preparationInfo
- Publication number
- JPH02286172A JPH02286172A JP1110684A JP11068489A JPH02286172A JP H02286172 A JPH02286172 A JP H02286172A JP 1110684 A JP1110684 A JP 1110684A JP 11068489 A JP11068489 A JP 11068489A JP H02286172 A JPH02286172 A JP H02286172A
- Authority
- JP
- Japan
- Prior art keywords
- filter
- platelet
- fiber
- diameter
- average
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000835 fiber Substances 0.000 claims abstract description 45
- 210000000265 leukocyte Anatomy 0.000 claims description 41
- 238000000926 separation method Methods 0.000 claims description 2
- 239000004745 nonwoven fabric Substances 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- -1 polypropylene Polymers 0.000 abstract description 4
- 239000004743 Polypropylene Substances 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 239000000155 melt Substances 0.000 abstract description 2
- 229920000728 polyester Polymers 0.000 abstract description 2
- 229920001155 polypropylene Polymers 0.000 abstract description 2
- 238000009987 spinning Methods 0.000 abstract description 2
- 238000012856 packing Methods 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 46
- 230000035699 permeability Effects 0.000 description 11
- 229920001410 Microfiber Polymers 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
- B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- External Artificial Organs (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、輸血をL1的とした体板処理フィルター、さ
らに詳しくは、出血傾向のある患者に輸血される濃縮血
小板血漿専の血小板製剤から効率的かつ安全に、混入し
た白血球を除去するためのフィルターに関する。Detailed Description of the Invention (Field of Industrial Application) The present invention provides a body plate treatment filter for blood transfusion as L1, and more specifically, a platelet preparation exclusively for concentrated platelet plasma transfused to patients with bleeding tendency. This invention relates to a filter for efficiently and safely removing contaminated white blood cells.
(従来の技術)
輸血に対する近年のシえ力は、従来の全血輸血に代って
、患者が7姿とする面板成分のみを輸血する成分輸血が
好まれる様になっており、出血傾向のある患者には、止
血効果の高い濃縮血小板血漿等の血小板製剤を繰り返し
輸血する場合が多い。(Prior art) In recent years, the trend towards blood transfusions has been to replace conventional whole blood transfusions with component transfusions in which only the face plate component of the patient is transfused, reducing bleeding tendency. Some patients often receive repeated transfusions of platelet products, such as platelet plasma concentrate, which have a high hemostasis effect.
しかしながら、血小板製剤は遠心分離法によって作成さ
れるため、血小板と白血球の密度差が小さいことから、
血小板製剤には大量の白血球が混入している。白血球の
型に関しては、組織適合性抗原と関連しており、供血者
と受血者との間で型が一致することは、極めてまれであ
り、そのため、輸血を受けた患者体内には、混入した白
血球により杭内血球抗体が産生され、発熱、悪寒、頭痛
、吐き気、アレルギー反応などの副作用を起こすことが
ある。さらに、輸血された血小板の患者体内での生存率
が、混入白血球が少ないほど良いとの報告もある。(岩
永隆行ら、輸血学会誌27、197−198.(+98
1))以I−のような理由から、血小板輸血に関し゛C
1混入白血球の除去の必要性が強く唱えられている。However, since platelet preparations are made by centrifugation, the difference in density between platelets and white blood cells is small.
Platelet preparations contain large amounts of white blood cells. The type of white blood cells is related to histocompatibility antigens, and it is extremely rare for the type of leukocytes to match between the donor and the recipient. The white blood cells produced by the patient produce blood cell antibodies, which can cause side effects such as fever, chills, headache, nausea, and allergic reactions. Furthermore, it has been reported that the survival rate of transfused platelets within a patient's body is better as the number of contaminated leukocytes decreases. (Takayuki Iwanaga et al., Journal of the Society of Blood Transfusion 27, 197-198. (+98
1)) For the following reasons, there are concerns regarding platelet transfusions.
The necessity of removing 1-contaminated leukocytes is strongly advocated.
血小板製剤より白血球を除去する方法には、遠心分離に
よる方法があるが、これは装置が高価であること、白血
球の除去率、血小板の回収率共に低いこと、操作が複雑
であり、献血時、輸血時のオンライン処理ができない等
の問題がある。One method for removing leukocytes from platelet preparations is by centrifugation, but this method requires expensive equipment, low leukocyte removal rate and low platelet recovery rate, and is complicated to operate. There are problems such as the inability to process blood transfusions online.
・方近年、極細繊維不織布フィルターを用いた白血球除
去装置が開発され、赤血球製剤中の白血球除去に使用さ
れている。(例えば特開昭6l−276584)これら
の白血球除去装置は、赤血球製剤中の白血球を効率よく
除去でき、装置も小型で操作も容易であるが、血小板も
同時に分離除去してしまうため、血小板製剤中の白血球
を除去する用途には使用できない。-Recently, leukocyte removal devices using ultrafine fiber nonwoven filters have been developed and are used to remove leukocytes from red blood cell preparations. (For example, Japanese Patent Application Laid-Open No. 61-276584) These leukocyte removal devices can efficiently remove leukocytes from red blood cell preparations, and are small and easy to operate, but platelets are also separated and removed at the same time. It cannot be used to remove white blood cells inside.
(発明が解決しようとする課題)
従来までの血小板製剤中から1目1u球除去を什う方法
では、白血球除去効率が低い、あるいは白血球除去効率
を高めると血小板回収ヰ(が低ドするといった課題があ
る。(Problems to be Solved by the Invention) The conventional method of removing 1 u cell from platelet preparations has problems such as low leukocyte removal efficiency, or that platelet recovery decreases when leukocyte removal efficiency is increased. There is.
本発明は、濃縮血小板、血漿等の血小板製剤から効率的
かつ安全に混入した白血球を除去するためのフィルター
を提供することをtj的とする。An object of the present invention is to provide a filter for efficiently and safely removing contaminated leukocytes from platelet preparations such as platelet concentrates and plasma.
(課題を解決するためのL段)
従来までの不織布による白血球除去フィルターは繊維直
径が1〜21mであり、白血球除去効率は高いが、同時
に血小板も除去してしまう。そこで本発明者らは、フィ
ルター繊維径と白血球および血小板除去性の関係につい
て鋭意検討を行った結果、繊維径、繊維間隙、フィルタ
ー表面積、処理速度、処理温度を調整することにより、
白血球と血小板の選択性を制御しうろことを見い出した
。(L stage for solving the problem) Conventional leukocyte removal filters using nonwoven fabrics have fiber diameters of 1 to 21 m, and have a high leukocyte removal efficiency, but also remove platelets at the same time. Therefore, the present inventors conducted extensive studies on the relationship between filter fiber diameter and leukocyte and platelet removal properties, and found that by adjusting the fiber diameter, fiber gap, filter surface area, processing speed, and processing temperature,
We found that scales control the selectivity of leukocytes and platelets.
すなわち、従来までの不織布による白血球除去フィルタ
ーの繊維よりも太い繊維径を有するフィルターを用い、
体温付近の処理温度で比較的ゆっくりした速度で処理す
ることにより、白血球除去効率を保ったままで、血小板
のフィルターへの吸着を抑えうることを見い出し、本発
明に至った。In other words, using a filter with a larger fiber diameter than the fibers of conventional non-woven leukocyte removal filters,
The present inventors have discovered that adsorption of platelets to the filter can be suppressed while maintaining leukocyte removal efficiency by performing treatment at a treatment temperature close to body temperature at a relatively slow rate, leading to the present invention.
すなわち、本発明のフィルターは、繊維の・y向直径が
2.0〜10.07mである繊維が次式で定義される繊
維間隙の平均円相当直径が16.0〜35.0−になる
ように充填されたフィルターであることを特徴とする。That is, in the filter of the present invention, fibers having a diameter in the y direction of 2.0 to 10.07 m have an average circular equivalent diameter of 16.0 to 35.0 m in the fiber gaps defined by the following formula. It is characterized by being a filter filled with
γ 璃
1)、、:繊維間隙の平均円相当直径(ptm )γ
:繊維の・1ノ均直径(戸)
ρ :繊維の密度(、g/c品)
γIm=フィルターの嵩密度(g / cJ )繊維径
を2.0pm以1−1繊維間隙の平均円相当直径を18
.0/ffl以14とすることで血小板透過率を高める
ことができる。一方、繊維径を10.0戸以−りとする
とフィルターは嵩高になってしまい装置が大きくなり、
平均円相当直径を35.0/i#I以L−とすると白血
球の除去率が低下してしまい好ましくない。さらに好ま
しい範囲は繊維直径が3.0〜8.OIJIm繊維間隙
の・l/均相当直径が16〜3.0.0を虐である。γ 1),: Average circular equivalent diameter (ptm) of fiber gaps γ
: Uniform diameter of the fiber (unit) ρ : Density of the fiber (g/c product) γIm = Bulk density of the filter (g/cJ) Equivalent to the average circle of the 1-1 fiber gap when the fiber diameter is 2.0 pm or more diameter to 18
.. Platelet permeability can be increased by setting it to 0/ffl or more to 14. On the other hand, if the fiber diameter is 10.0 mm or more, the filter becomes bulky and the device becomes large.
If the average equivalent circle diameter is less than 35.0/i#I, the leukocyte removal rate will decrease, which is not preferable. A more preferable range is a fiber diameter of 3.0 to 8. OIJIm fiber gap .l/uniform equivalent diameter is 16 to 3.0.0.
ま゛た、本発明においては、フィルター繊維の表面積が
、血小板製剤処理[n20−当り0.1〜0.5./で
あることが望ましい。繊維表面積が処理量20 、Q当
りo、trj以ドとすると白血球を吸着する面積が狭く
なり、白血球を吸着しきれな(なり、0.5r/以1−
とすると吸着面積が大きくなりすぎ、血小板除去性が増
加し、好ましくない。Furthermore, in the present invention, the surface area of the filter fiber is 0.1 to 0.5 per n20 treated with platelet preparation. / is desirable. If the fiber surface area is less than 20 o, trj per Q, the area for adsorbing leukocytes becomes narrower, and the area for adsorbing leukocytes becomes smaller (0.5 r/or more than 1-
If so, the adsorption area becomes too large and the platelet removal property increases, which is not preferable.
フィルターの形状は不織布状が好ましい。The shape of the filter is preferably non-woven fabric.
本発明の血小板製剤中の白血球分離フィルターにおいて
は、[−記装置の【11位面積当りの血小板製剤中
きが好ましい。t11位面積当りの処理速度を0.51
aQ / mln/(T11以ドとすることで、良好な
白血球除去率と血小板透過率が得られる。0 、5 m
Q / mtn/c+a以−Lにすると白血球除去率、
血小板透過率の低下、圧力損失の増加がみられ好ましく
ない。In the leukocyte separation filter in platelet preparations of the present invention, it is preferable to use platelet preparations per [-11th area of the device]. t11th processing speed per area 0.51
By setting aQ/mln/(T11 or higher, good leukocyte removal rate and platelet permeability can be obtained. 0, 5 m
Q/mtn/c+a to -L, leukocyte removal rate,
This is unfavorable because it causes a decrease in platelet permeability and an increase in pressure loss.
さらに本発明の血小板製剤中の白血球分離方法において
は処理温度が20℃以上37℃以下であることを特徴と
する。20℃以下の処理温度では血小板が繊維に非特異
的に吸着してしまい、37℃以上では血小板や血漿が熱
によりダメージを受けるため好ましくない。Furthermore, the method for separating leukocytes in platelet preparations of the present invention is characterized in that the processing temperature is 20°C or higher and 37°C or lower. At a treatment temperature of 20° C. or lower, platelets will non-specifically adsorb to the fibers, and at a treatment temperature of 37° C. or higher, platelets and plasma will be damaged by heat, which is not preferable.
本発明のフィルター素材は必ずしも限定されるものでは
ないが、良好な白血球除去能を41°し、補体活性が少
ない生体適合性に優れる疎水性のポリプロピレンやポリ
エステル系素材等が望ましい。The filter material of the present invention is not necessarily limited, but hydrophobic polypropylene or polyester materials, which have good leukocyte removal ability of 41°, low complement activity and excellent biocompatibility, are desirable.
この様な素材から本発明の装置に用い得る極細繊維不織
布を得る方法としては、メルトブロー紡糸法が特に好ま
しい。As a method for obtaining ultrafine fiber nonwoven fabrics that can be used in the apparatus of the present invention from such materials, melt blow spinning is particularly preferred.
以ド実施例により本発明の効果ならびに、より詳細な説
明を加える。Hereinafter, the effects of the present invention and more detailed explanation will be added by way of Examples.
実施例
本発明における実施例および比較例では、いずれもメル
トブロー法により得られたポリエチレンテレフタレート
の不織布を用いた。濃縮血小板血漿は、抗凝固剤として
ACDMを用いた新鮮牛血液を1500rp閣、151
n遠心分離しヒ澄みを採取することにより得た。実験は
濃縮血小板血漿をポンプを用い定速で送板し、200.
1!の処理を杼い、白血球除去率、血小板透過率、装置
人[」、出[1間の圧力損失を測定した。白血球数、血
小板数は、コールタ−カウンターにより計測した。Examples In both the Examples and Comparative Examples of the present invention, nonwoven fabrics of polyethylene terephthalate obtained by a melt blowing method were used. Concentrated platelet plasma was prepared using fresh bovine blood using ACDM as an anticoagulant at 1500 rpm, 151
It was obtained by centrifugation and collecting the clarified water. In the experiment, concentrated platelet plasma was pumped at a constant rate of 200.
1! The leukocyte removal rate, platelet permeability, pressure loss between the apparatus and the output were measured. The number of white blood cells and platelets were measured using a Coulter counter.
また不織布極細繊維の糸径は、走査電r顕微鏡により写
真撮影を行い、1種類のサンプルについて50点の計測
を行うことにより決定した。Further, the thread diameter of the non-woven ultrafine fibers was determined by taking photographs with a scanning electron microscope and measuring 50 points for one type of sample.
なお、ポリエチレンテレフタレート繊維の比重としては
1.38g/cJを用いて繊維間隙の平均円相当直径を
算出した。Note that the average equivalent circle diameter of the fiber gaps was calculated using 1.38 g/cJ as the specific gravity of the polyethylene terephthalate fibers.
〔実施例1〕
平均糸径3.5戸の極細繊維不織布を3.4g採取し、
フィルター面積20cJ1嵩密度0.20g / cJ
に充填した。実施例で記述した方法に従い、処理温度3
7℃送液1f& 10 J/+inで定速処理を行った
。尚この時の繊維間隙の平均円相当直径は24戸であり
、血小板製剤処理]′i12〇−当りの不織布フィルタ
ー繊維の表面積は0.28♂である。[Example 1] 3.4 g of ultrafine fiber nonwoven fabric with an average thread diameter of 3.5 mm was collected,
Filter area 20cJ1 Bulk density 0.20g/cJ
was filled. According to the method described in the examples, treatment temperature 3
Constant rate treatment was performed at 7° C. and 1f&10 J/+in. The average equivalent circle diameter of the fiber gaps at this time was 24 mm, and the surface area of the nonwoven filter fibers per platelet preparation treatment was 0.28♂.
tit位面積当りの処理速度はO−5yaQ/ 1n/
cJである。結果はTabte lに示すように、白血
球除去率、血小板透過率共に90%以上であり、圧力損
失も少なく良好な性能を示した。The processing speed per tit area is O-5yaQ/1n/
It is cJ. As shown in Table 1, the leukocyte removal rate and platelet permeability were both 90% or higher, indicating good performance with little pressure loss.
〔実施例2〕
実施例1と同様なモジュールを用い、処理温度のみ20
℃とし他の条件は実施例1と同様にして1tった。結果
はTable 1に示すように、白血球除去率、血小板
透過率共に90%以。l−であり圧力損失も少な(良好
な性能を示した。[Example 2] Using the same module as in Example 1, only the processing temperature was 20
The temperature was 1 t, and the other conditions were the same as in Example 1. As shown in Table 1, the leukocyte removal rate and platelet permeability were both over 90%. 1-, and the pressure loss was small (showing good performance).
〔比較例1〕
実施例1と同様なモジュールを用い、処理温度のみ10
℃とし他の条件は実施例1と同様にして行った。結果は
Table 1に示すように血小板透過率が低ドする問
題点を小した。[Comparative Example 1] Using the same module as in Example 1, only the processing temperature was 10
℃ and the other conditions were the same as in Example 1. The results, as shown in Table 1, alleviated the problem of low platelet permeability.
〔比較例2〕
実施例1と同様なモジュールを用い、送液量のみ25□
(j/m!nとし他の条件は実施例1と同様にして実験
を行った。結果はTable 1に示すように、自1f
l1球の除去率の低下、圧力損失の増加などの問題点を
示した。この時のtltl面位当りの処理速度は1 、
2+mQ/sin/cT11であった。[Comparative Example 2] Using the same module as in Example 1, only the amount of liquid sent was 25□
(j/m!n, and other conditions were the same as in Example 1.The results are as shown in Table 1.
Problems such as a decrease in the removal rate of 11 spheres and an increase in pressure loss were shown. At this time, the processing speed per tltl surface position is 1,
2+mQ/sin/cT11.
〔比較例3〕
実施例1と同様な極細繊維不織布(″−17均糸径3.
5戸)を3.4g採取し、嵩密度0.30g/ cri
lに充填し、実施例1と同様の条件で実験を4+’うた
。結果はTable lに示すように血小板透過率が低
ドする問題点を示した。なお、この時の繊維間隙の%I
/、均円相当直径は12.6−と狭かった。[Comparative Example 3] The same ultrafine fiber nonwoven fabric as in Example 1 (''-17 yarn diameter 3.
5 households) was collected, and the bulk density was 0.30 g/cri.
The experiment was carried out under the same conditions as in Example 1. As shown in Table I, the results showed a problem of low platelet permeability. In addition, %I of the fiber gap at this time
/, the equivalent circle diameter was as narrow as 12.6-.
〔比較例4〕
実施例1と同様な極細繊維不織布(平均糸径3.5s)
を3.4g採取し、嵩密度0.11g/cIilに充填
し、実施例1と同様の条件で実験を行った。結果はTa
ble 1に示すように、白血球除去率が低ドする問題
点を示した。この時の繊維間隙の円相当直径は40.4
μ層と広かった。[Comparative Example 4] Ultrafine fiber nonwoven fabric similar to Example 1 (average thread diameter 3.5 s)
3.4g of the sample was collected and filled to a bulk density of 0.11g/cIil, and an experiment was conducted under the same conditions as in Example 1. The result is Ta
As shown in ble 1, the problem was that the leukocyte removal rate was low. The equivalent circle diameter of the fiber gap at this time is 40.4
The μ layer was wide.
〔実施例3〕
平均糸径8.o/Jjの極細繊維不織布を7.8g採取
し、嵩密度0.40g/cnlに充■nシ、実施例1と
同様の条件で実験を行った。面この時の繊維間隙の平均
円相当直径は19.67Jであり、血小板製剤処理量2
0 mQ当りの不織布フィルター繊維の表面積は0.2
8♂である。結果はTable lに示すように白血球
除去率、血小板透過率共に90%以−1−であり、圧力
損失も少なく良好な性能を示した。[Example 3] Average yarn diameter: 8. An experiment was conducted under the same conditions as in Example 1, with 7.8 g of O/Jj microfiber nonwoven fabric taken and filled to a bulk density of 0.40 g/cnl. The average circular equivalent diameter of the fiber gaps at this time was 19.67 J, and the platelet preparation throughput was 2.
The surface area of nonwoven filter fibers per 0 mQ is 0.2
He is 8 years old. As shown in Table I, both the leukocyte removal rate and the platelet permeability were 90% or higher -1-, indicating good performance with little pressure loss.
〔比較例5〕
・V均糸径2.0μmの極細繊維不織布を1.9g採取
し、嵩密度0.15g/criに充填し、実施例1と同
様の条件で実験を打った。尚この時の繊維間隙の・ヒ装
置相当直径は1B、4sであり、血小板製剤処理;鋒2
0−当りの不織布フィルター繊維の表面積は0.281
/である。結果はTable 1に示すように、血小板
透過率が低ドする問題点を示した。[Comparative Example 5] - 1.9 g of ultrafine fiber nonwoven fabric with a V-leveled yarn diameter of 2.0 μm was collected and filled to a bulk density of 0.15 g/cri, and an experiment was conducted under the same conditions as in Example 1. The equivalent diameter of the fiber gap at this time was 1B, 4s, and the platelet preparation treatment;
The surface area of nonwoven filter fibers per 0.0 - 0.281
/ is. As shown in Table 1, the results showed the problem of low platelet permeability.
〔比較例6〕
実験例1と同様な極細繊維不織布(平均糸径3.5/j
J1)を1.0・g採取し、嵩密度0.20g/cTi
Iに充填し、実施例1と同様の条件で実験を打った。尚
この時の繊維間隙の平均円相当直径は24/jjであり
、血小板製剤処理H20mQ当りの不織布フィルター繊
維の表面積は0.081/である。[Comparative Example 6] Ultrafine fiber nonwoven fabric similar to Experimental Example 1 (average yarn diameter 3.5/j
1.0 g of J1) was collected, and the bulk density was 0.20 g/cTi.
The experiment was carried out under the same conditions as in Example 1. The average circular equivalent diameter of the fiber gaps at this time was 24/jj, and the surface area of the nonwoven filter fibers per 20 mQ of platelet preparation treatment was 0.081/.
結果はTable 1に示すように白血球除去率が低下
する問題点を示した。As shown in Table 1, the results showed a problem in which the leukocyte removal rate decreased.
〔比較例7〕
実験例1と同様な極細繊維不織布(平均糸径3.51I
II)を11.2g採取し、嵩密度0.20g / c
taに充填し、実施例1と同様の条件で実験を行った。[Comparative Example 7] Ultrafine fiber nonwoven fabric similar to Experimental Example 1 (average thread diameter 3.51I
11.2g of II) was collected, and the bulk density was 0.20g/c.
The experiment was conducted under the same conditions as in Example 1.
尚この時の繊維間隙の平均円相当直径は241i11で
あり、血小板製剤処理酸2〇−当りの不織布フィルター
繊維の表面積は0.92./である。The average equivalent circle diameter of the fiber gaps at this time was 241i11, and the surface area of the nonwoven filter fibers per 20 - of platelet preparation treated acid was 0.92. / is.
結果はTable lに示すように血小板透過率が低ド
する問題点を示した。As shown in Table I, the results showed a problem of low platelet permeability.
以F余白
(発明の効果)
本発明によるとき濃縮血小板、血漿等の血小板製剤から
効率的かつ安全に混入した白血球を除去することを11
工能とする。Margin (Effects of the Invention) According to the present invention, it is possible to efficiently and safely remove contaminated leukocytes from platelet preparations such as platelet concentrates and plasma.
It is considered as a skill.
Claims (1)
が次式で定義する繊維間隙の平均円相当直径が16.0
〜35.0μmになるように充填された血小板製剤中の
白血球分離フィルター。 D_H=γ×(ρ−γ_m)/γ_m D_H:繊維間隙の平均円相当直径(μm) γ:繊維の平均直径(μm) ρ:繊維の密度(g/cm^3) γ_m:フィルターの嵩密度(g/cm^3)(1) Fibers with an average fiber diameter of 2.0 to 10.0 μm have an average circular equivalent diameter of the fiber gap defined by the following formula of 16.0
A leukocyte separation filter in a platelet preparation filled to a thickness of ~35.0 μm. D_H=γ×(ρ-γ_m)/γ_m D_H: Average circular equivalent diameter of fiber gap (μm) γ: Average diameter of fiber (μm) ρ: Density of fiber (g/cm^3) γ_m: Bulk density of filter (g/cm^3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1110684A JP2870796B2 (en) | 1989-04-27 | 1989-04-27 | Leukocyte separation filter in platelet preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1110684A JP2870796B2 (en) | 1989-04-27 | 1989-04-27 | Leukocyte separation filter in platelet preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02286172A true JPH02286172A (en) | 1990-11-26 |
JP2870796B2 JP2870796B2 (en) | 1999-03-17 |
Family
ID=14541828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1110684A Expired - Fee Related JP2870796B2 (en) | 1989-04-27 | 1989-04-27 | Leukocyte separation filter in platelet preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2870796B2 (en) |
-
1989
- 1989-04-27 JP JP1110684A patent/JP2870796B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2870796B2 (en) | 1999-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5298165A (en) | Method for removing leukocytes and a filter system for removing the same | |
US5679264A (en) | Gas plasma treated porous medium and method of separation using same | |
KR960009418B1 (en) | Filtering device for blood platelet | |
JPH0663131A (en) | Method for selectively removing leucocyte | |
JPH05501368A (en) | Blood processing equipment and blood processing methods for human blood transfusion | |
EP1016426B1 (en) | Leukocyte-removing filter material | |
JP4646114B2 (en) | Plasma preparation or serum preparation and method for producing the same | |
JPH04187206A (en) | Leucocyte separator and production of leucocyte separating material | |
JPH02286172A (en) | Leucocyte separating filter in platelet preparation | |
JP3250833B2 (en) | Leukocyte selective capture filter material | |
JP2004129550A (en) | Method for separating and recovering monocyte | |
JP3208132B2 (en) | Blood component separation method | |
JPH02286171A (en) | Leucocyte separating filter | |
JPH01256971A (en) | Leucocyte removing material and filter | |
JPH0720872B2 (en) | Leukocyte removal filter and leukocyte removal method | |
JPH03242152A (en) | Blood treating device | |
JPS5995051A (en) | Apparatus for fractionating and purifying blood | |
JPH0221917A (en) | Blood filter and production thereof | |
JPH1057477A (en) | White blood cell removing filter material and white blood cell removing filter device | |
JP2001347116A (en) | White blood cell removing filter device | |
RU2053797C1 (en) | Method of circulating immune complex removing | |
RU2056864C1 (en) | Method of removal of circulating immune complexes from plasma blood | |
Sweeney et al. | Mechanisms of leukodepletion by filtration | |
Lundberg et al. | A biochemical study of the influence upon blood cells by four different leukocyte-removal filters | |
Slater | Autologous blood transfusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080108 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090108 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |